Sarda Proteins Ltd. (SRDAPRT) — Tipsheet https://tipsheet.markets/company/srdaprt/ Every Tipsheet Editorial note covering Sarda Proteins Ltd. (SRDAPRT), newest first. Grounded in BSE/NSE primary-source filings. en-in Sun, 05 Jul 2026 14:22:18 GMT Sarda Proteins loses MD, three directors after Onix open offer https://tipsheet.markets/srdaprt-sarda-proteins-loses-md-three-directors-after-onix-open-offer-119179/ https://tipsheet.markets/srdaprt-sarda-proteins-loses-md-three-directors-after-onix-open-offer-119179/ Sat, 04 Jul 2026 17:49:47 GMT Chirag Thummar resigns as managing director; Shirish Savaliya appointed immediately. CFO becomes chairperson, new CFO named. Authorized capital jumps eightfold to ₹100 crore. Chirag Thummar resigns as managing director; Shirish Savaliya appointed immediately. CFO becomes chairperson, new CFO named. Authorized capital jumps eightfold to ₹100 crore.

What’s new

  • Managing director Chirag Thummar resigns; Shirish Savaliya appointed for five years.
  • CFO Yagnik Satasiya becomes non-executive chairperson; Drashti Delvadiya new CFO.
  • Three more directors resign: Bipinkumar Savalia, Khilan Savaliya, independent Chintan Bhatt.
  • Authorized capital raised to ₹100 cr from ₹13 cr; objects clause altered.

Why it matters

A wholesale leadership reset days after Onix Renewable's open offer for 19.28% signals a decisive shift in control. For a nano-cap with ₹84 cr market cap and trailing ROE of 0.2%, such upheaval creates strategic uncertainty. Execution risk is high, and the new management's alignment with Onix remains unstated.

What we’re watching

  • Whether Onix secures board seats in coming weeks.
  • New MD Shirish Savaliya's first strategic communication.
  • Potential delisting or fundraising using the ₹100 cr headroom.

The full read

Sarda Proteins has seen a near-total boardroom reset. Managing director Chirag Thummar resigned on July 4, and the board immediately appointed Shirish Savaliya for five years. Former CFO Yagnik Satasiya moved to non-executive chairperson; Drashti Delvadiya became CFO. Three other directors, Bipinkumar Savalia, Khilan Savaliya, and independent Chintan Bhatt, also quit, all effective immediately. The timing is key: this comes days after Onix Renewable completed its 19.28% open offer. The board also approved an eightfold increase in authorized equity capital to ₹100 crore, a move previously flagged. For a company with a market cap of just ₹84 crore and trailing ROE of 0.2%, such sweeping change carries execution risk. It's a lot. The open question is whether the new team operates as an extension of Onix or pursues its own strategy.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial Sarda Proteins plans eight-fold jump in authorized capital to ₹100 cr https://tipsheet.markets/srdaprt-sarda-proteins-plans-eight-fold-jump-in-authorized-capital-to-100-cr-117960/ https://tipsheet.markets/srdaprt-sarda-proteins-plans-eight-fold-jump-in-authorized-capital-to-100-cr-117960/ Wed, 01 Jul 2026 16:29:38 GMT Nano-cap edible oil company prepares for major equity dilution; board to meet on 4 July 2026 to seek shareholder approval for capital increase. Nano-cap edible oil company prepares for major equity dilution; board to meet on 4 July 2026 to seek shareholder approval for capital increase.

What’s new

  • Board to meet 4 July to hike authorized capital from ₹13 cr to ₹100 cr
  • Also to alter MOA objects clause and seek shareholder ratification via EGM
  • Move suggests groundwork for a significant equity issuance after Onix entry

Why it matters

For a company with just ₹84 cr market cap, an eight-fold increase in authorized capital is a massive signal of intent. It implies management is preparing to raise substantial equity, likely through rights or preferential allotment, which would deeply dilute existing shareholders. The absence of specific quantum or mode leaves the timing and structure of any potential capital raise uncertain.

What we’re watching

  • Shareholder response at the EGM: will retail holders approve the dilution?
  • Whether the capital raise is linked to Onix Renewable's expansion plans
  • Any detail on mode of issuance: rights, preferential, or QIP

The full read

Sarda Proteins is preparing for something big. Its board will meet on 4 July 2026 to propose an eight-fold increase in authorised equity share capital from ₹13 crore to ₹100 crore. For a nano-cap with a market capitalisation of just ₹84 crore, that magnitude of headroom is a clear signal: management is laying the groundwork for a substantial equity issuance, most likely a rights issue or preferential allotment. The filing also includes amending the objects clause of the MOA and calling an extraordinary general meeting to secure shareholder approval. The timing follows the recent change in control by Onix Renewable, suggesting the capital raise may be tied to their growth plans. But the meeting is just a procedural first step. No amount, mode, or timeline has been disclosed. What is certain: if the full headroom is used, existing shareholders face severe dilution. Without specifics, the per-share impact remains uncertain.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial